AI Article Synopsis
- There is limited cumulative data on the effectiveness of radiation monotherapy for treating Merkel cell carcinoma (MCC), especially for patients who cannot undergo surgery.
- A systematic review of literature revealed treatment outcomes for 68 patients, showing varying rates of relapse and mortality across different stages of MCC, particularly highlighting higher relapse and death rates in stage III patients.
- The findings suggest that radiation monotherapy could be a viable option for inoperable stage I-III MCC patients, but further prospective studies are needed to confirm these results conclusively.
Article Abstract
Background: Cumulative data on radiation monotherapy for Merkel cell carcinoma (MCC) is lacking.
Objective: We sought to synthesize all available data on treatment outcomes for radiation monotherapy for inoperable stage I-III MCC.
Methods: We performed a systematic review of the current literature. Articles published in English in the PubMed database up to July 29, 2016, were evaluated.
Results: Eight case reports, 4 case series, and 6 retrospective studies, yielding 68 patients, were included in our analysis. Of the 24 stage I/II patients treated with local irradiation, 6 (25%) relapsed and 1 (4%) died from MCC. Of the 24 stage I/II patients treated with local and regional nodal irradiation, 5 (21%) relapsed and 2 (8%) died from MCC. Of the 20 stage III patients treated with local and regional nodal irradiation, 12 (60%) relapsed and 7 (35%) died from MCC.
Conclusions: Radiation monotherapy appears to be a reasonable treatment modality for patients with inoperable stage I-III MCC. Further investigation with prospective studies is needed to draw definitive conclusions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955084 | PMC |
| http://dx.doi.org/10.5826/dpc.0802a15 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The efficacy and safety of belzutifan inhibitor in patients with advanced or metastatic clear cell renal cell carcinoma: a meta-analysis.
BMC Pharmacol Toxicol
December 2024
Department of Critical Care Medicine, Shandong Provincial Maternal and Child Health Care Hospital, Jinan, 250014, China.
Background: The belzutifan is a hypoxia inducible factor-2 alpha (HIF-2α) inhibitor for the treatment of advanced or metastatic clear cell renal cell carcinoma (mccRCC) and has exhibited good safety and efficacy in clinical trials. We conducted a meta-analysis of relevant studies to further clarify the efficacy and safety of belzutifan for the treatment of mccRCC.
Methods: Multiple databases and abstracts from major scientific meetings were systematically reviewed for eligible articles published before June 1, 2024.
Partial or Focal Brachytherapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
Br J Radiol
December 2024
Princess Margaret Cancer Centre, University Health Network, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Introduction: Recent advances in image-guided brachytherapy have allowed for treatment volume reduction in the treatment of prostate cancer, with the aim to optimize disease control and reduce toxicities. This systematic review reports on the efficacy and safety of focal brachytherapy for treatment of patients with localized prostate cancer.
Methods: Medline, Embase, Web of Science and Cochrane were searched from inception to July 2023.
Efficacy and safety of ibrutinib in central nervous system lymphoma: A systematic review and meta-analysis.
Crit Rev Oncol Hematol
December 2024
Hamad Medical Corporation, Doha, Qatar. Electronic address:
Background: Primary central nervous system lymphoma (CNSL) is a rare, aggressive non-Hodgkin lymphoma confined to the CNS. Although radiation and chemotherapy, particularly high-dose methotrexate (HD-MTX), are effective treatments, the relapse rates remain high, prompting the exploration of novel therapeutic options. Ibrutinib, an irreversible Bruton tyrosine kinase (BTK) inhibitor, has shown promise in various B-cell malignancies, including CNSL.
View Article and Find Full Text PDFCombining serum inflammatory markers and clinical factors to predict survival in metastatic urothelial carcinoma patients treated with immune checkpoint inhibitors.
Ther Adv Med Oncol
December 2024
Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, No. 123, Dapi Road, Niaosong District, Kaohsiung City 833, Taiwan.
Article Synopsis
- This study investigates the use of serum inflammatory markers as prognostic indicators for survival in patients with metastatic urothelial carcinoma (mUC) receiving immune checkpoint inhibitors (ICIs).
- Data from two medical centers in Taiwan were analyzed, focusing on markers like neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), to assess their impact on overall and progression-free survival.
- The findings suggest that specific inflammatory markers, along with other clinical factors, can effectively predict patient outcomes, emphasizing the need for reliable prognostic tools in mUC treatment.
Successful Treatment With Lorlatinib Monotherapy for Secondary Central Nervous System Oligometastatic Disease in Refractory Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer.
Cureus
November 2024
Hematology and Medical Oncology, Tripler Army Medical Center, Honolulu, USA.
The anaplastic lymphoma kinase (ALK) gene plays crucial roles in both normal brain development and oncogenesis, particularly in non-small cell lung cancer (NSCLC). Metastatic ALK-positive NSCLC is characterized by ALK tyrosine kinase domain rearrangements, prompting the use of ALK tyrosine kinase inhibitors (TKIs) to target the mutation. While first-line treatment options include alectinib, brigatinib, and lorlatinib per National Comprehensive Cancer Network (NCCN) guidelines, therapeutic challenges arise in cases of disease progression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!